Advertisement

Topics

Latest Vitekta (elvitegravir) NewsRSS

23:21 EDT 20th October 2017 | BioPortfolio

Global Scaling Chemical Inhibitor Market Research Report Forecast 2017 to 2021 [Report Updated: 16102017] Prices from USD $2800

The Global Scaling Chemical Inhibitor Market Research Report Forecast 20172021 is a valuable source of insightful data for business strategists. It provides the Scaling Chemical Inhibitor industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research analysts provide an elaborate description of the value chain and its distribut...

Hereditary Angioedema HAE C1 Esterase Inhibitor [C1INH] Deficiency Global Clinical Trials Review, H2, 2017 [Report Updated: 15092017] Prices from USD $2500

Hereditary Angioedema HAE C1 Esterase Inhibitor [C1INH] Deficiency Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial report, Hereditary Angioedema HAE C1 Esterase Inhibitor [C1INH] Deficiency Global Clinical Trials Review, H2, 2017" provides an overview of Hereditary Angioedema HAE C1 Esterase Inhibitor [C1INH] Deficiency clinical trials scenario. This report provides top l...

U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review

LYNPARZA Has the Potential to Offer a New Treatment Option for Patients with Germline BRCA-Mutated, HER2-Negative Metastatic Breast Cancer Regulatory Submission Acceptance Is the First for a PARP Inhibitor Beyond Ovarian Cancer AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the...

US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review

LYNPARZA has the potential to offer a new treatment option for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer Regulatory submission acceptance is first for a PARP inhibitor beyond ovarian cancer AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US...

Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

BURLINGAME, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present data on lead checkpoint inhibitor CPI-444 from its ongoing Phase 1/1b study in an oral session at the Society for Immunotherapy of C...

Pfizer next-gen ALK inhibitor could ease lung cancer burden

Loralatinib could help the big pharma bolster its position in the NSCLC market as Xalkori faces increased competition. 

Withdrawing α-Blockers in BPH Patients Receiving Combination Therapy

After a patient with benign prostatic hyperplasia receives 1 year of both an α-blocker and a 5α-reductase-inhibitor, the α-blocker usually can be stopped.

AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema

LOUISVILLE, Colo., Oct. 17, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“AntriaBio” or the “Company”) (OTCQB:ANTB), a biopharmaceutical company focused on developing therapies to address significant unmet medical needs, today announced that it is advancing the first development candidates from its oral plasma kallikrein inhibitor (PKI) portfolio. The two preclinical programs are AB402 f...

Immune Checkpoint Inhibitor Therapy Has Revolutionized Cancer Treatment

But rheumatoid arthritis and polymyalgia rheumatica can be added to the list of adverse events.

NonReceptor Tyrosine Kinase Inhibitor Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, NonReceptor Tyrosine Kinase InhibitorMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across NonReceptor Tyrosine Kinase Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics a...

Inovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder Cancer

PLYMOUTH MEETING, Pa., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced initiation of a phase 1b/2 immuno-oncology trial to evaluate Genentech/Roche’s atezolizumab (TECENTRIQ®) in combination with Inovio’s INO-5401, a T cell activating immunotherapy encoding multiple antigens, and INO-9012, an immune activator encoding IL-12. The multi-center,...

Inducible Nitric Oxide Synthase iNOS or Type II NOS Inhibitor Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, Inducible Nitric Oxide Synthase iNOS or Type II NOS InhibitorMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Inducible Nitric Oxide Synthase iNOS or Type II NOS Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage...

Global Cancer Angiogenesis Inhibitor Market Research Report Forecast 2017 to 2022 [Report Updated: 09102017] Prices from USD $2800

Delivery of the Report will take 23 working days once order is placed.The Global Cancer Angiogenesis Inhibitor Market Research Report Forecast 20172022 is a valuable source of insightful data for business strategists. It provides the Cancer Angiogenesis Inhibitor industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research anal...

Matrix Metalloproteinase MMP Inhibitor Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $2000

DelveInsight's, Matrix Metalloproteinase MMP InhibitorMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Matrix Metalloproteinase MMP Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics...

A Bit About Biopharma Investing

Well, as predicted here (and many other places), Merck announced yesterday that they are indeed not going to try to seek approval for their CETP inhibitor, anacetrapib. That’s despite an ostensibly positive Phase III trial, but it apparently wasn’t positive enough to take the risk of bringing this drug before the FDA (or to the

CETP class shelved as Merck pulls out

Development of the last major CETP inhibitor has now ceased, ending a decade of pharma setbacks. 

Merck & Co. Provides Update On Anacetrapib Development Program

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced that the company will not submit applications for regulatory approval for anacetrapib, Mercks investigational cholesteryl ester transfer protein (CETP) inhibitor. The decision follows a thorough...

Entasis Receives Second CARB-X Award, Providing Up To $10.1 Million For Development Of Non-Beta-Lactam PBP Inhibitor Program

WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics...

FDA Grants Priority Review For Potential New Indication For Eli Lilly's Verzenio (Abemaciclib) As Initial Treatment Of Advanced Breast Cancer

INDIANAPOLIS, Oct. 12, 2017 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for its New Drug Application (NDA) for Verzenio (abemaciclib), a cyclin-dependent kinase (CDK)4 & 6 inhibitor...

Global Protein Kinase Inhibitor Market Research Report Forecast 2017 to 2021 [Report Updated: 18092017] Prices from USD $2800

The Global Protein Kinase Inhibitor Market Research Report Forecast 20172021 is a valuable source of insightful data for business strategists. It provides the Protein Kinase Inhibitor industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research analysts provide an elaborate description of the value chain and its distributor a...

VERZENIOTM (abemaciclib) Approved for Treatment of Metastatic Breast...

Biologics, Inc. , a McKesson Specialty Health oncology pharmacy services company, has been selected by Eli Lilly and Company to be in the limited distribution network for VERZENIOTM , Eli Lilly's first oral oncolytic indicated for metastatic breast cancer. Approved by the U.S. Food and Drug Administration on September 28, 2017, VERZENIO is a CDK inhibitor selective for CDK4 and CDK6.

Global Tyrosine Kinase Inhibitor Market Research Report Forecast 20172022 [Report Updated: 18092017] Prices from USD $2800

Delivery of the Report will take 4872 hours once order is placed.The Global Tyrosine Kinase Inhibitor Market Research Report Forecast 20172022 is a valuable source of insightful data for business strategists. It provides the Tyrosine Kinase Inhibitor industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research analysts provid...

Human medicines European public assessment report (EPAR): Genvoya, elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide, Revision: 11, Authorised

BclxL Protein Inhibitor Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, BclxL Protein InhibitorMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across BclxL Protein Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics assessment of BclxL Protein I...

Clovis looks to expand label for PARP inhibitor

The biotech submitted an application to expand use of Rubraca to include maintenance therapy, a key step if it is to catch up with its PARP rivals.

Quick Search
Advertisement
 

review and buy Vitekta (elvitegravir) market research data and corporate reports here